Concepedia

Author

Rabab Gaafar

Cairo UniversityORCID

Also Known As

Gaafar Ragab, R Gaafar, R. Gaafar, R. M. Gaafar, R., Gaafar, R.M Gaafar, R.M. Gaafar, R.M.M. Gaafar, RABAB GAAFAR, Rabab Gaafar

136

Publications

3.8K

Citations

29

H-Index

31

Concepts

All Affiliations

Cairo UniversityEuropean Organisation for Research and Treatment of CancerEuropean Organisation for Research and Treatment of CancerChildren Cancer HospitalHeidelberg University
RG

About

Rabab Gaafar is an author at Cairo University specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

19

29

1.5K

2

Health Sciences

12

13

897

3

Cell Biology

1

1

22

4

Immunology

1

1

17

5

Obstetrics

1

1

149

Rabab Gaafar

×

46

Publications

3.5K

Citations

27

H-Index

YearCitations

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

Jan P. van Meerbeeck, Rabab Gaafar, Christian Manegold,

Journal of Clinical Oncology

2005

621

Three-Arm Randomized Study of Two Cisplatin-Based Regimens and Paclitaxel Plus Gemcitabine in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group—EORTC 08975

Egbert F. Smit, J.P.A.M van Meerbeeck, P. Lianes,

Journal of Clinical Oncology

2003

351

Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial

Paul Van Schil, Paul Baas, Rabab Gaafar,

European Respiratory Journal

2010

240

Vorinostat in patients with advanced malignant pleural mesothelioma who have progressed on previous chemotherapy (VANTAGE-014): a phase 3, double-blind, randomised, placebo-controlled trial

Lee M. Krug, Hedy L. Kindler, Hilary Calvert,

The Lancet Oncology

2015

219

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

Fabio Efficace, Andrew Bottomley, Egbert F. Smit,

Annals of Oncology

2006

182

Nintedanib in combination with pemetrexed and cisplatin for chemotherapy-naive patients with advanced malignant pleural mesothelioma (LUME-Meso): a double-blind, randomised, placebo-controlled phase 3 trial

Giorgio V. Scagliotti, Rabab Gaafar, Anna K. Nowak,

The Lancet Respiratory Medicine

2019

164

Breast cancer in Egypt:a review of disease presentation and detection strategies

Sherif Omar, Hussein Khaled, Rabab Gaafar,

Eastern Mediterranean Health Journal

2021

149

Phase II, open-label, randomized study (SIGN) of single-agent gefitinib (IRESSA) or docetaxel as second-line therapy in patients with advanced (stage IIIb or IV) non-small-cell lung cancer

Tanja Čufer, Eduard Vrdoljak, Rabab Gaafar,

Anti-Cancer Drugs

2006

149

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03)

Rabab Gaafar, Veerle Surmont, Giorgio V. Scagliotti,

European Journal of Cancer

2011

119

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)

Thomas Bachelot, Eva Ciruelos, Fabio Puglisi,

Annals of Oncology

2019

111

Page 1